Collapse Skip to main content

MedEngine Newsletter: Nordic RWE Landscape

In the pharmaceutical industry, we have witnessed a dramatic expansion of the use of real-world data throughout the product’s lifecycle.
Currently, real-world evidence (RWE) is an essential element of safety and effectiveness assessments, market access processes, and clinical development of innovative products, to name a few.

And when generating RWE, there’s no data like Nordic data.

In the latest episode of Expert Opinions, MedEngine’s Scientific Consultant Mirkka Koivusalo shares her views on why the Nordics provide unique opportunities for RWE research.

“When generating RWE, there’s no data like Nordic data.” 

At MedEngine, we specialize in Nordic RWE projects. We have a deep understanding of data sources, study permit practices, and regulations in each country. We also have local team members in Denmark, Finland, and Sweden, who are responsible for handling the local study permit procedures to ensure effective management of study procedures.

If you are interested in learning more about the Nordic RWE landscape, please contact us at We’re always happy to share our insights and experiences!


🦸 Ps. a Pro tip: Type your email below and sign up for our newsletter to get the latest news and Expert Opinions directly to your inbox.

Klaus Elfving

Klaus Elfving

Klaus Elfving is MedEngine's Digital Content Lead.